| Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA DA Nathanson, B Gini, J Mottahedeh, K Visnyei, T Koga, G Gomez, ... Science 343 (6166), 72-76, 2014 | 574 | 2014 |
| Metabolic state of glioma stem cells and nontumorigenic cells E Vlashi, C Lagadec, L Vergnes, T Matsutani, K Masui, M Poulou, ... Proceedings of the National Academy of Sciences 108 (38), 16062-16067, 2011 | 539 | 2011 |
| mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc K Masui, K Tanaka, D Akhavan, I Babic, B Gini, T Matsutani, A Iwanami, ... Cell metabolism 18 (5), 726-739, 2013 | 407 | 2013 |
| An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers GR Villa, JJ Hulce, C Zanca, J Bi, S Ikegami, GL Cahill, Y Gu, KM Lum, ... Cancer cell 30 (5), 683-693, 2016 | 274 | 2016 |
| Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment K Tanaka, T Sasayama, Y Irino, K Takata, H Nagashima, N Satoh, ... The Journal of clinical investigation 125 (4), 1591-1602, 2015 | 230 | 2015 |
| Altered cellular metabolism in gliomas—An emerging landscape of actionable co-dependency targets J Bi, S Chowdhry, S Wu, W Zhang, K Masui, PS Mischel Nature Reviews Cancer 20 (1), 57-70, 2020 | 224 | 2020 |
| mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystine-glutamate antiporter xCT Y Gu, CP Albuquerque, D Braas, W Zhang, GR Villa, J Bi, S Ikegami, ... Molecular cell 67 (1), 128-138. e7, 2017 | 173 | 2017 |
| Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma W Wei, YS Shin, M Xue, T Matsutani, K Masui, H Yang, S Ikegami, Y Gu, ... Cancer cell 29 (4), 563-573, 2016 | 173 | 2016 |
| EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer I Babic, ES Anderson, K Tanaka, D Guo, K Masui, B Li, S Zhu, Y Gu, ... Cell metabolism 17 (6), 1000-1008, 2013 | 170 | 2013 |
| Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies K Masui, TF Cloughesy, PS Mischel Neuropathology and applied neurobiology 38 (3), 271-291, 2012 | 166 | 2012 |
| Molecular classification of gliomas K Masui, PS Mischel, G Reifenberger Handbook of clinical neurology 134, 97-120, 2016 | 156 | 2016 |
| mTORC2 in the center of cancer metabolic reprogramming K Masui, WK Cavenee, PS Mischel Trends in Endocrinology & Metabolism 25 (7), 364-373, 2014 | 154 | 2014 |
| A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments K Masui, B Gini, J Wykosky, C Zanca, PS Mischel, FB Furnari, ... Carcinogenesis 34 (4), 725-738, 2013 | 132 | 2013 |
| Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance K Masui, K Tanaka, S Ikegami, GR Villa, H Yang, WH Yong, TF Cloughesy, ... Proceedings of the National Academy of Sciences 112 (30), 9406-9411, 2015 | 117 | 2015 |
| Glial progenitors in the brainstem give rise to malignant gliomas by platelet‐derived growth factor stimulation K Masui, SO Suzuki, R Torisu, JE Goldman, P Canoll, T Iwaki Glia 58 (9), 1050-1065, 2010 | 58 | 2010 |
| The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas B Gini, C Zanca, D Guo, T Matsutani, K Masui, S Ikegami, H Yang, ... Clinical Cancer Research 19 (20), 5722-5732, 2013 | 56 | 2013 |
| Cancer metabolism as a central driving force of glioma pathogenesis K Masui, WK Cavenee, PS Mischel Brain tumor pathology 33, 161-168, 2016 | 44 | 2016 |
| Metabolic reprogramming in the pathogenesis of glioma: Update K Masui, H Onizuka, WK Cavenee, PS Mischel, N Shibata Neuropathology 39 (1), 3-13, 2019 | 43 | 2019 |
| mTOR complexes as a nutrient sensor for driving cancer progression M Harachi, K Masui, Y Okamura, R Tsukui, PS Mischel, N Shibata International journal of molecular sciences 19 (10), 3267, 2018 | 42 | 2018 |
| Protease‐resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion H Honda, K Sasaki, H Minaki, K Masui, SO Suzuki, K Doh‐ura, T Iwaki Neuropathology 32 (2), 124-132, 2012 | 40 | 2012 |
